Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
NextCure Inc
NASDAQ NXTC
Data sourced from
and
and
NextCure Inc Return on Equity (ROE) 5 year CAGR for the year ending December 31, 2023
NextCure Inc Return on Equity (ROE) 5 year CAGR is NA for the year ending December 31, 2023. Return on equity (ROE) measures the profitability of a company relative to its shareholders' equity. It is calculated by dividing the net income by the shareholders' equity. This ratio indicates the return generated for each unit of shareholders' equity invested in the company. A higher ROE suggests better profitability and value creation for shareholders. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
NextCure Inc Return on Equity (ROE) for the year ending December 31, 2022 was -41.45%, a -39.40% change year over year.
-
NextCure Inc Return on Equity (ROE) for the year ending December 31, 2021 was -29.73%, a -163.11% change year over year.
-
NextCure Inc Return on Equity (ROE) for the year ending December 31, 2020 was -11.30%, a -7.68% change year over year.
-
NextCure Inc Return on Equity (ROE) for the year ending December 31, 2019 was -10.49%, a -121.61% change year over year.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: NXTC
| CEO | Mr. Michael S. Richman MSBA |
| IPO Date | May 9, 2019 |
| Location | United States |
| Headquarters | 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 |
| Employees | 82 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Key trends
StockViz Staff
September 19, 2024
Any question? Send us an email